Psoriasis Vulgaris
Conditions
Brief summary
Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet. Not getting enough sleep can lead to health problems like heart attacks, diabetes, and even cancer. Since individuals with psoriasis have these same health problems, getting better sleep may help to keep them happier and healthier. This study will look at how individuals with psoriasis sleep and if their sleep is different than indivuduals without psoriasis.
Detailed description
A growing body of literature has revealed that individuals with psoriasis are more likely to report sleep disturbance when compared to the general population. The cross-sectional study presented here will allow the investigators to objectively and rigorously measure sleep architecture in psoriasis patients and compare it to healthy controls, If sleep dysfunction is confirmed in this population, then clinical interventions such as screening for sleep disturbance or promoting sleep hygiene could lead to meaningful improvements in patients' health, longevity, and overall quality of life.
Interventions
PSG is the gold standard for objectively measuring sleep in the laboratory setting. The procedure consists of electrodes measuring brain activity (electroencephalography, EEG), eye movements (electrooculography, EOG), muscle activity (electromyography, EMG), respiratory events, snoring activity, blood oxygen saturation, and body position. Video surveillance during the sleep study can also monitor for itching events that occur during the night.
Sponsors
Novartis Pharmaceuticals
National Psoriasis Foundation
University of California, San Francisco
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Patients with a diagnosis of moderate to severe plaque type psoriasis confirmed by the principal investigator. Moderate to severe psoriasis will be defined as affected BSA ≥3%. Healthy controls will be age and sex matched (see below) subjects with no prior or current history of psoriasis. 2. Are at least 18 years of age 3. Psoriasis has been stable over the last 3 months 4. Psoriasis is either untreated or treated only with topicals at the current time (see
Exclusion criteria
for washout times) 5. Subjectively reported poor sleep quality using the Pittsburg Sleep Quality Index (PSQI) (defined as a global score \>5) 6. Fluent in English 7. Demonstrate understanding of the study and willingness to participate as evidenced by voluntary informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sleep efficiency | Average over 3 consecutive nights of sleep | Sleep efficiency is defined as the percentage of time spent asleep while in bed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total sleep time | Average over 3 consecutive nights of sleep | Total sleep time is the total amount of sleep time recorded during the total recording time (each night) |
| Sleep onset latency | Average over 3 consecutive nights of sleep | Sleep onset latency is defines as the duration of time from turning off the light to falling asleep. |
| Wake after sleep onset | Average over 3 consecutive nights of sleep | Wake after sleep onset is defined as the time between when they first fall asleep to when they become fully awake. |
Countries
United States
Outcome results
None listed